Acadia Healthcare’s (ACHC) Q3 results disappointed, with FY25 EBITDA guidance cut by 5% and additional negative surprises weighing on sentiment, Cantor Fitzgerald tells investors in a research note. While a guidance reduction was expected after the September preannouncement, higher bad debt, legal costs, and ongoing volume pressures further dampened outlook, the firm says. Cantor has a Neutral rating and $25 price target on the stock.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare COO Nasser Khan resigns
- Acadia Healthcare lowers FY25 adjusted EPS $2.35-$2.45 from $2.45-$2.65
- Acadia Healthcare taking ‘decisive action to drive improved performance’
- Acadia Healthcare sees FY25 EPS $2.35-$2.45, consensus $2.47
- Acadia Healthcare reports Q3 adjusted EPS 72c, consensus 66c
